Par Pharmaceutical (PRX) Tops Q4 EPS by 3c
Tweet Send to a FriendGet Alerts PRX Hot Sheet
Price: $49.98 --0%
EPS Growth %: +92.9%
Financial Fact:
(Loss) income from discontinued operations: 0
Today's EPS Names:
CO, JW-A, FDS, More
EPS Growth %: +92.9%
Financial Fact:
(Loss) income from discontinued operations: 0
Today's EPS Names:
CO, JW-A, FDS, More
Trade PRX Now!
Par Pharmaceutical (NYSE: PRX) reported Q4 EPS of $0.78, $0.03 better than the analyst estimate of $0.75. Revenue for the quarter came in at $253.6 million versus the consensus estimate of $230.31 million.
For earnings history and earnings-related data on Par Pharmaceutical (PRX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Par Pharmaceutical (PRX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- PVH Corp. (PVH) Tops Q1 EPS by 56c; Issues Q2 EPS, Revs Outlook
- Lentuo International (LAS) Swings to Q1 Loss; Updates on Expansion
- La-Z-boy, Inc. (LZB) Tops Q4 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
